MedPath

Clinical study about the safety of Suvorexant for severe sleep apnea syndrome

Phase 4
Conditions
Sleep Apnea Syndrome
Registration Number
JPRN-jRCTs041180086
Lead Sponsor
Imaizumi Kazuyoshi
Brief Summary

There was no significant difference in the AHI of patients with severe sleep apnea before and after taking Suvorexant.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

The patient who received enough explanation about this study, and provides agreement in the document.

Exclusion Criteria

The patient 19 years or younger at the time of the agreement acquisition

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Apnea hypopnea index on PSG
Secondary Outcome Measures
NameTimeMethod
Epworth sleepiness scale
© Copyright 2025. All Rights Reserved by MedPath